Dr Julie Graff speaks to ecancer at the 2020 ASCO GU meeting at San Francisco about the results from cohorts 4 & 5 of the KEYNOTE-199 trial.

She explains the differences between the various cohorts and specifically gave results data for cohorts 4 and 5, which looks promising.

The toxicities were as expected, with some manageable skin rash.

From this, Dr Graff explains that a new study will be formed, KEYNOTE-641.